^
Association details:
| Biomarker: | LDH elevation |
|---|---|
| Cancer: | Melanoma |
| Drug: | AiRuiKa (camrelizumab) (PD1 inhibitor) + AiTan (rivoceranib) (VEGFR-2 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Apatinib in combination with camrelizumab, a humanized immunoglobulin G4 monoclonal antibody against programmed cell death-1, in patients with metastatic acral melanoma.
Published date:
05/19/2021
Excerpt:
Eligible participants were adult pts (aged 18 to 75) with histologically confirmed unresectable stage or distant metastatic acral melanoma….Pts received camrelizumab at 200mg intravenous infusion every 2 weeks, in combination with apatinib 250 mg orally once a day....Univariate analysis showed high LDH level was negatively associated with PFS.
DOI:
10.1200/JCO.2021.39.15_suppl.9539
Trial ID:
